Purpose {#S0001}
=======

Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer \[[@CIT0001]--[@CIT0004]\]. Standard treatment for radiotherapy usually involves the use of external beam radiotherapy followed by 3 channel intracavitary brachytherapy, using the 3 channel Fletcher Suite applicator (Elekta AB, Stockholm, Sweden) given the higher survival rates \[[@CIT0005], [@CIT0006]\]. For tumors involving the parametrium or pelvic side wall, 3 channel Fletcher suite applicator may not provide adequate dosimetric coverage of the tumor, and hence lead to higher recurrence rate \[[@CIT0007]\]. Combined intracavitary and interstitial cervical brachytherapy, using either the Vienna Ring applicator (Elekta AB, Stockholm, Sweden) or Utrecht applicator (Elekta AB, Stockholm, Sweden) plus interstitial needles placed in the parametrium area has shown to improved tumor dosimetric coverage, leading to higher local control as compared to non interstitial treatment \[[@CIT0008], [@CIT0009]\]. As this procedure is done in an operating theatre (OT) setting requiring the use of general or epidural anaesthesia, access to such resources is limited. To overcome the OT access issue, outpatient combined intracavitary and interstitial cervical brachytherapy is an attractive option. The aim of this article is to share and discuss the use of combined intracavitary and interstitial cervical brachytherapy in an outpatient setting at the author\'s institution, and explores the issues and barriers for implementation and suggestions to overcome such barriers.

Rationale for combined intracavitary and interstitial treatment {#S0002}
===============================================================

Results from the Vienna group has demonstrated that to have effective local control, the minimal dose to the high risk clinical target volume (HR CTV) should be greater or equal than 87 Gy \[[@CIT0010]\]. Without the use of interstitial needles, such dose to the HR CTV is difficult to achieve due to the adjacent bowel and rectal anatomy, limiting the HR CTV to below 87 Gy. However, with interstitial needles in place, one is able to achieve the HR CTV should be greater or equal than 87 Gy, yet respecting the organ at risk dose of the adjacent normal tissues \[[@CIT0008]--[@CIT0010]\].

Patient selection {#S0003}
=================

Patients with cervical stage 2B and stage 3B with parametrial residual disease post chemotherapy and external beam radiotherapy would benefit the most from interstitial cervical brachytherapy, especially for patients with residual bilateral parametrial disease \[[@CIT0010]\] ([Figure 1](#F0001){ref-type="fig"}). Compared to 3D Fletcher suit applicator, the greatest advantage of combined intracavitary and interstitial brachytherapy is the superior dosimetric coverage of the HR CTV, allowing for better therapeutic ratio \[[@CIT0008]--[@CIT0010]\]. This permits the HR CTV to be above 87 Gy, thus improving local control rates. This form of adaptive brachytherapy is personalized to each individual patient\'s anatomy in order to lead to the best results. Other patient selection factors include fitness to undergo anaesthesia, suitable pelvic anatomy, and tumor topography for appropriate applicator placement, as well as availability to preplanning clinical examination and imaging findings.

![Patients with bilateral parametrium disease benefit the greatest from interstitial brachytherapy](JCB-7-25405-g001){#F0001}

Method of insertion {#S0004}
===================

The entire radiotherapy treatment should be completed within 7 weeks, hence the brachytherapy should ideally commence at the end of external beam radiotherapy and should be avoided with concurrent chemotherapy \[[@CIT0011]--[@CIT0013]\]. With regards to the brachytherapy dose, there is a range of doses used as recommended by the American Brachytherapy Society guidelines but at our institution, our brachytherapy treatment schema is 7 Gy × 4 fractions, treating a maximum of 2 fractions a week with at least 8 hours in between fractions \[[@CIT0012], [@CIT0013]\]. Two to 3 days prior to the procedure, a pre-brachytherapy planning magnetic resonance imaging (MRI) scan is performed to evaluate the extend of the parametrium, identification of important normal tissue structures such as the uterine arteries, as well as to determine where to place the interstitial needles to achieve optimal coverage \[[@CIT0014], [@CIT0015]\]. Consultation with the radiologist may be useful in aiding the pre-brachytherapy planning.

Twenty-four hours prior to the procedure, oral fleet is given to the patient to ensure adequate bowel preparation. By reducing the chance of fecal material or flatus in the bowel, this reduces the likelihood of the bowel being adjacent to the HR CTV region \[[@CIT0012]\]. On the day of the procedure, the patient is fasted 6 hours before to allow for moderate sedation using a combination of oxycodone 5 mg capsules and midazolam given by the anesthetist. After positioning the patient in a lithotomy position, a formal examination of the cervix and the parametrium and a per rectum is done digitally to assess the extent of the tumor. With the speculum in place, a paracervical block is then performed, injecting 2% lignocaine into the 2, 4, 8, 10 o\'clock positions in the cervical parametrium area ([Figure 2](#F0002){ref-type="fig"}). This is to anaesthetize the adjacent area to facilitate the insertion of the interstitial needles in the parametrium \[[@CIT0016]\].

![Paracervical block. Paracervical anaesthetic block is placed at the 2, 4, 8, 10 o\'clock position in the cervical parametrium area as denoted by the white dots](JCB-7-25405-g002){#F0002}

Once the Utrecht applicator is *in situ*, the planning of where to insert and the length of the needle insertion is determined from the pre-brachytherapy MRI, avoiding important anatomical structures such as the uterine artery. Once determined, usually 1-2 needles are inserted into the parametrium. The vaginal is then packed with gauze and the applicator secured, and the patient is then transferred to the computed tomography (CT) scanner. Prior to the CT scan, the bladder is filled with 200 mls of normal saline to facilitate the movement of the small bowel away from the HR CTV region \[[@CIT0017]\]; 5 mm CT scan of the abdo-pelvis area is then acquired. At this juncture, the radiation oncologist should review the location and depth of needle insertion, as well as any adjustment to the length of the needles is then done and the CT scan reacquired once more till the depth of needles adequately covers the HR CTV region.

The HR CTV and the various organs at risk (OAR) are then contoured as per the Groupe Européen de Curiethérapie (GEC) and the European Society for Radiotherapy & Oncology (GEC-ESTRO) protocol \[[@CIT0018], [@CIT0019]\]. The prescription will be 7 Gy × 4 fractions. The various OAR recommendations are listed in [Table 1](#T0001){ref-type="table"} \[[@CIT0016], [@CIT0020]\].

###### 

Prescription dose and organs at risk values used at our centre

  ---------------------------------
  **Prescription dose:**
   EBRT: 50.4 Gy in 28 fractions
   HDR: 7 Gy × 4 fractions
  **Point A dose to be reported**
  **HR CTV:** D~90~ ≥ 87 Gy
  **Rectal D~2cc~:** ≤ 75 Gy
  **Bladder D~2cc~:** ≤ 100 Gy
  ---------------------------------

Discussion {#S0005}
==========

Combined intracavitary and interstitial brachytherapy has been clinically proven to show better dosimetric coverage, leading to higher local control rates. However, the uptake of this procedure remains low despite these excellent results. Barriers to combined intracavitary and interstitial brachytherapy implementation can be summed up into doctor related, patient related, and procedure related \[[@CIT0021]\].

Doctor related barriers are mainly due to inadequate training in the use of combined intracavitary and interstitial cervical brachytherapy devices, and being unfamiliar with contouring using the GEC-ESTRO protocol. To encourage upgrading of clinical skills and continued medical education, European society of therapeutic radiation oncology (ESTRO) has setup a teaching school with annual courses on combined intracavitary and interstitial gynaeoncology brachytherapy including mix of didactic lectures, contouring sessions, and discussion on clinically challenging cases, which the author found beneficial, useful, and highly recommended to readers interested in setting up a interstitial gynaeoncology program \[[@CIT0022]\]. In addition, International Atomic Energy and Agency (IAEA) and BrachyAcademy (Elekta) also conduct similar educational courses, focusing more on implementation issues and clinical hands on sessions \[[@CIT0023], [@CIT0024]\].

Patient related barriers are few and are concentrating on poor communication or a lack of knowledge of why interstitial brachytherapy is indicated or needle phobia. With clear and concise communication during the informed consent process, as well as involving the patient by explaining the insertion process using the pre-planning MRI scan, the author\'s experience suggest that most patients are generally less fearful and more inclined to undergo this procedure. One suggestion by the author is to explain the procedure using a power point presentation, detailing the insertion process, evidence of why it is better than Fletcher suite applicator, and the clinical results of the interstitial experience with associated potential side effects of this procedure helps patient to understand the procedure better and are hence less apprehensive or less needle phobic.

Procedure related barriers include the lack of access to MRI scanners on the implant day or the limited access to OT resources and issue of adequate regional anaesthesia if done as outpatient.

MRI versus CT scan for planning {#S20006}
-------------------------------

Currently, the gold standard for combined intracavitary and interstitial is MRI planning \[[@CIT0025], [@CIT0026]\]. However, for most radiotherapy centres in the worlds, access to MRI scanners is an issue due to resource limitation \[[@CIT0027]\]. However, most radiotherapy centres have a CT scanner in house, which is used for everyday radiotherapy simulation planning process. To better correlate MRI planning using CT scans, a suggestion is to perform a pre brachytherapy insertion MRI 2-3 days before the actual insertion day. This pre insertion MRI is crucial as it allows the radiation oncologist to determine the extent of the parametrial disease, placement of interstitial needles, as well as location of important anatomical structure such as the uterine arteries to avoid \[[@CIT0028]\].

Alternatively, MRI could be obtained as a first fraction with subsequent fractions using CT scans \[[@CIT0013]\]. Conclusions from the Vienna group using this method showed that this combination method is feasible and best used for small tumours with minimal parametrial involvement only. For tumors with higher volume of residual disease in the parametrium, the authors recommend avoiding such a technique.

In addition, there are published guidelines on using CT scans for contouring regions of interest \[[@CIT0029]--[@CIT0032]\]. Studies evaluating CT scan contouring have suggested that with good preplanning using information from clinical examination of the cervix and the use of the pre insertion MRI scan, there is good correlation between MRI and CT scan for contouring \[[@CIT0033]--[@CIT0035]\]. This would facilitate more centres adopting combined intracavitary and interstitial brachytherapy using CT scans for contouring.

Outpatient versus inpatient {#S20007}
---------------------------

A major resource limitation at the author\'s centre is the access to OT facilities. At the author\'s centre, insertion of the Fletcher suite applicator is done in the radiotherapy department under moderate sedation on an outpatient basis. Given that the Utrecht applicator insertion is similar to the 3 channel applicator insertion except for the interstitial component, this too may be done as an outpatient procedure. To minimize pain and discomfort, moderate sedation together with a paracervical block is used to anaesthesize the patient to provide better pain relief. At our centre, we have successfully treated patients in an outpatient centre using combination of moderate anaesthesia with paracervical block, and have found the procedure well tolerated with minimal post procedure complications, which is comparable to other radiotherapy centres \[[@CIT0033], [@CIT0034]\]. Hence, in the author\'s own experience, outpatient combined intracavitary and interstitial cervical brachytherapy may be a safe and feasible option when done together with pre insertion MRI brachytherapy planning and should be advocated.

Additional advantages in an outpatient setting include no need to compete for inpatient beds with other medical disciplines, lower risk of hospital acquired infection, lower financial cost to patient, and better workflow protocol within the department.

Anaesthesia: locoregional blocks with moderate sedation versus general anaesthesia {#S20008}
----------------------------------------------------------------------------------

Regional anaesthesia, using a paracervical block is a simple and effective method to provide adequate anaesthesia around the uterus, cervix, and parametrial region. Under visual inspection, 2% of lignocaine solution is injected into the paracervical region creating the anaesthesia block. Advantage of lignocaine is that it is a safe and fast acting with a short duration of anaesthesia (about 1 hour), compared to Bupivacaine, which is known to cause life threatening cardiotoxicity. If longer anaesthesia is required, safer alternatives to Bupivacaine include Ropivacaine and Chirocaine; both having safer cardiotoxicity profiles compared to Bupivacaine. Complications of administering such a block include risk of bleeding, iatrogenic infection, and intravascular injection. In the author\'s centre, the learning curve for administration of such a block is about 5 patients done under supervision before one becomes competent. Advantages of the paracervical block include avoiding an epidural or general anaesthesia, which generally carries a higher complication risk \[[@CIT0035]\].

Conclusions {#S0009}
===========

Combined intracavitary and interstitial cervical brachytherapy should be the standard of care for patients with residual parametrial disease post chemotherapy and external beam radiotherapy, given the superior dosimetric coverage translating into higher local control rates. Ideally, outpatient insertion should be the preferred method and suggestions to overcome such barriers in an outpatient setting have been discussed. Sharing of clinical experience from other centres adopting outpatient combined intracavitary and interstitial cervical treatment is needed to validate this procedure as an outpatient procedure.
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